Journal of Vascular Surgery
Volume 31, Issue 2 , Pages 396-405 , February 2000

The caput medusae of hypercoagulability

Received 23 April 1999 ,Accepted 19 July 1999.

References 

  1. Bick RL, Kaplan H. Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis. Med Clin North Am. 1998;82:409–458
  2. Stassen JM, Nystrom A. A historical review of hemostasis, thrombosis, and antithrombotic therapy. Ann Plast Surg. 1997;39:317–329
  3. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253–260
  4. Myers KA, King RB, Scott DF, Johnson N, Morris PJ. The effects of smoking on the late patency of arterial reconstruction in the legs. Br J Surg. 1978;65:267–271
  5. Greenhalgh RM, Laing SP, Cole PV, Taylor GW. Smoking and arterial reconstruction. Br J Surg. 1981;68:605–607
  6. Roald HE, Lyberg T, Dedichen T, Hamers M, Kierulf P, Westvik AB, et al.  Collagen-induced thrombosis formation in flowing nonanticoagulate human blood from habitual smokers and nonsmoking patients with severe peripheral atherosclerotic disease. Arterioscler Thromb Vasc Biol. 1995;15:128–132
  7. Blann AD, Steel C, McCollum CN. Influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices. Thromb Haemost. 1997;78:1093–1096
  8. Calaitges JG, Liem TK, Spadone D, Nichols WK, Silver D. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg. 1999;29:785–786
  9. Kikta MJ, Keller MP, Humphrey PW, Silver D. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?. Surgery. 1993;114:705–710
  10. Slocum MM, Adams JG, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg. 1996;23:839–843
  11. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol. 1987;69:557–565
  12. Insko EK, Haskal ZJ. Antiphospholipid syndrome: patterns of life-threatening and severe recurrent vascular complications. Radiology. 1997;202:319–326
  13. Ahn SS, Kalunian K, Rosove M, Moore WS. Postoperative thrombotic complications in patients with the lupus anticoagulant: increased risk after vascular procedures. J Vasc Surg. 1988;7:749–756
  14. Williams FM, Hunt BJ. The antiphospholipid syndrome and vascular surgery. Cardiovasc Surg. 1998;6:10–16
  15. Sipes SL, Weiner CP. Venous thromboembolic disease in pregnancy. Semin Perinatol. 1990;14:103–118
  16. Hellgren M, Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. Gynecol Obstet Invest. 1981;12:141–154
  17. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, et al.  Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183–1188
  18. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al.  Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9–13
  19. Jordan WM. Pulmonary embolism. Lancet. 1961;2:1146–1147
  20. Schafer AI. The hypercoagulable states. Ann Intern Med. 1985;102:814–828
  21. Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, et al.  Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996;76:729–734
  22. Winkler UH. Blood coagulation and oral contraceptives. Contraception. 1998;57:203–209
  23. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 1996;312:83–88
  24. Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med. 1998;244:27–32
  25. Iba T, Kidokoro A, Yagi Y. The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg. 1998;187:321–329
  26. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816–823
  27. Kidokoro A, Iba T, Fukunaga M, Yagi Y. Alterations in coagulation and fibrinolysis during sepsis. Shock. 1996;5:223–228
  28. Betteridge DJ, El Tahir KE, Reckless JP, Williams KI. Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Eur J Clin Invest. 1982;12:395–398
  29. Colwell JA, Winocour PD, Lopes-Virella M, Halushka PV. New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med. 1983;75:67–80
  30. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica. 1965;13:516–530
  31. Sagar S, Nairn D, Stamatakis JD, Maffei FH, Higgins AF, Thomas DP, et al.  Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet. 1976;1:1151–1154
  32. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 1993;341:134–138
  33. Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism: a study of three Dutch families. N Engl J Med. 1983;309:340–344
  34. Eldrup-Jorgensen J, Flanigan DP, Brace L, Sawchuk AP, Mulder SG, Anderson CP, et al.  Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg. 1989;9:334–341
  35. D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest. 1988;81:1445–1454
  36. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecoginized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004–1008
  37. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thromboembolic patients. Blood. 1993;82:1989–1993
  38. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504–1508
  39. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517–522
  40. Zoller B, Hillarp A, Berntorp E, et al.  Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med. 1997;48:45–58
  41. Koster T, Rosendaal FR, deRonde H, Briet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993;342:1503–1506
  42. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111–128
  43. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279–298
  44. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050
  45. Guba SC, Fink LM, Fonseca V. Hyperhomocystinemia: an emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol. 1996;106:709–722
  46. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703
  47. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al.  The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol. 1997;17:2418–2422
  48. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt 20210A) in venous thrombosis and arterial disease. Thromb Haemost. 1997;78:1430–1433
  49. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Ranhunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747–1750
  50. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem. 1997;43:1678–1683
  51. Tollefsen DM. Laboratory diagnosis of antithrombin and heparin cofactor II deficiency. Semin Thromb Hemost. 1990;16:162–168
  52. Robbins KC. Classification of abnormal plasminogens: dysplasminogenemias. Semin Thromb Hemost. 1990;16:217–220
  53. Rao AK, Sheth S, Kaplan R. Inherited hypercoagulable states. Vasc Med. 1997;2:313–320
  54. Pelletier S, Landi B, Piette JC, Ekert P, Coutellier A, Desmoulins C, et al.  Antiphospholipid syndrome as the second cause of non-tumerous Budd-Chiari syndrome. J Hepatol. 1994;21:76–80
  55. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut. 1997;40:798–800
  56. Levy PJ, Hornung CA, Haynes JL, Rush DS. Lower extremity ischemia in adults younger than forty years of age: a community-wide survey of premature atherosclerotic arterial disease. J Vasc Surg. 1994;19:873–881
  57. Ray SA, Rowley MR, Loh A, Talbot SA, Bevan DH, Taylor RS, et al.  Hypercoagulable states in patients with leg ischemia. Br J Surg. 1994;81:811–814
  58. Levy PJ, Gonzalez FM, Rush DS, Haynes JL. Hypercoagulable states as an evolving risk for spontaneous venous and arterial thrombosis. J Am Coll Surg. 1994;178:266–270
  59. Donaldson MC, Belkin M, Whittemore AD, Mannick JA, Longtine JA, Dorfman DM. Impact of activated protein C resistance on general vascular surgical patients. J Vasc Surg. 1997;25:1054–1060
  60. Ouriel K, Green RM, DeWeese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vasc Surg. 1996;23:46–51
  61. Donaldson MC, Weinberg DS, Belkin M, Whittemore AD, Mannick JA. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. J Vasc Surg. 1990;11:825–831

☆ Competition of interest: nil.

☆☆ Reprint requests: Dr Donald Silver, University of Missouri-Columbia, Department of Surgery, One Hospital Dr, Columbia, MO 65212.

★ 0741-5214/2000/$12.00 + 0  24/9/102322

PII: S0741-5214(00)90170-8

doi: 10.1016/S0741-5214(00)90170-8

Journal of Vascular Surgery
Volume 31, Issue 2 , Pages 396-405 , February 2000

Article Tools